Lenvatinib, as a type of TKI and one of the most potent inhibitors of VEGFR, can synergistically promote the production of EPO in hepatocellular carcinoma cells under hypoxic conditions, leading to the occurrence of polycythemia [23]. Here, EPO is linked to hepatocellular carcinoma.